Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: A pilot study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 4, 2006, Pages 714-717

  Lee, Bun Hee ^a   Kim, Yong Ku ^a   Park, Sun Hwa ^b  

^a Korea University College of Medicine   (South Korea)

^b Research Institute of Food and Nutritional Sciences   (South Korea)

Author keywords

Amisulpride; Aripiprazole; Hyperprolactinemia; Risperidone

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; LORAZEPAM; RISPERIDONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AMENORRHEA; ARTICLE; AUDITORY HALLUCINATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FEMALE SEXUAL DYSFUNCTION; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; MENSTRUAL IRREGULARITY; PILOT STUDY; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; SCORING SYSTEM; SLEEP DISORDER; SYMPTOMATOLOGY;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERPROLACTINEMIA; MIDDLE AGED; PILOT PROJECTS; PIPERAZINES; PROLACTIN; QUINOLONES; SCHIZOPHRENIA; TIME FACTORS;

EID: 33646525623     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.02.001     Document Type: Article

References (29)

1. Aihara K., Shimada J., Miwa T., Tottori K., Burris K.D., Yocca F.D., et al. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res 1003 (2004) 9-17
2. Anghelescu I., and Wolf J. Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report. J Clin Psychiatry 65 (2004) 1286-1287
3. Antai-Otong D. The art of prescribing. Principles of switching novel antipsychotic medications. Perspect Psychiatr Care 41 (2005) 45-47
4. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302 (2002) 381-389
5. Casey D.E., Carson W.H., Saha A.R., Liebeskind A., Ali M.W., Jody D., et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 166 (2003) 391-399
6. David S.R., Taylor C.C., Kinon B.J., and Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 22 (2000) 1085-1096
7. Goodnick P.J., Rodriguez L., and Santana O. Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother 3 (2002) 1381-1391
8. Grunder G., Carlsson A., and Wong D.F. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 60 (2003) 974-977
9. Haddad P.M., and Wieck A. Antispychotic-induced hyperprolactinemia: mechanism, clinical features and management. Drugs 64 (2004) 2291-2314
10. Inoue A., Seto M., Sugita S., Hide I., Hirose T., Koga N., et al. Differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary. Brain Res Mol Brain Res 55 (1998) 285-292
11. Jaber M., Robinson S.W., Missale C., and Caron M.G. Dopamine receptors and brain function. Neuropharmacology 35 (1996) 1503-1519
12. Jordan S., Koprivica V., Chen R., Tottori K., Kikuchi T., and Altar C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441 (2002) 137-140
13. Kapur S., Langlois X., Vinken P., Megens A.A., De Coster R., and Andrews J.S. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 302 (2002) 1129-1134
14. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 261-276
15. Kikuchi T., Tottori K., Uwahodo Y., Hirose T., Miwa T., Oshiro Y., et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-q uinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 274 (1995) 329-336
16. Kim Y.K., Kim L., and Lee M.S. Risperidone and associated amenorrhea: a report of 5 cases. J Clin Psychiatry 60 (1999) 315-317
17. Kopecek M., Bares M., Svarc J., Dockery C., and Horacek J. Hyperprolactinemia after low dose of amisulpride. Neuro Endocrinol Lett 25 (2004) 419-422
18. Lee B.H., Han C.S., Kim K.H., and Kim Y.K. Treatment in risperidone-induced amenorrhea. Int J Clin Pract 9 (2005) 29-34
19. Lusskin S.I., Cancro R., Chuang L., and Jacobson J. Prolactin elevation with ziprasidone. Am J Psychiatry 161 (2004) 1925
20. Maguire G. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 63 (2002) 56-62
21. McGavin J.K., and Goa K.L. Aripiprazole. CNS Drugs 16 (2002) 779-786
22. Mihara K., Suzuki A., Kondo T., Yasui-Furukori N., Ono S., Otani K., et al. Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol. Am J Med Genet 105 (2001) 271-274
23. National Institute of Mental Health. Clinical global impression scale. Psychopharmacol Bull 4 (1985) 839-841
24. Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M., Stock E., et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60 (2003) 681-690
25. Ramaswamy S., Vijay D., William M., Sattar S.P., Praveen F., and Petty F. Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol 19 (2004) 45-48
26. Reeves R.R., and Mack J.E. Worsening schizoaffective disorder with aripiprazole. Am J Psychiatry 161 (2004) 1308
27. Remington G., Chue P., Stip E., Kopala L., Girard T., and Christensen B. The crossover approach to switching antipsychotics: what is the evidence?. Schizophr Res 76 (2005) 267-272
28. Wahl R., and Ostroff R. Reversal of symptomatic hyperprolactinemia by aripiprazole. Am J Psychiatry 162 (2005) 1542-1543
29. *A1 allele. Br J Psychiatry 185 (2004) 147-151